NOX-A12

NOXXON to Attend the German Fall Conference on September 6 & 7, 2021

Retrieved on: 
Wednesday, August 25, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NOX-A12, Terminology, Merck Sharp & Dohme Federal Credit Union, Immune system, Communication, GLORIA, Brain, Radiation, MGMT, Tumor microenvironment, ESMO, TME, Safety, Patient, Pembrolizumab, Pancreatic cancer, Neoplasm, German Autumn, Pharmaceutical industry, Medical imaging, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

The capital market conference for small and mid-cap companies organized by Equity Forum will take place in the form of virtual one-on-one meetings.

Key Points: 
  • The capital market conference for small and mid-cap companies organized by Equity Forum will take place in the form of virtual one-on-one meetings.
  • The conference aims at bringing together public company representatives across sectors with investors, analysts, financial journalists, intermediaries and financial industry experts.
  • NOXXONs CEO, Aram Mangasarian, will be available for meetings on both conference days.
  • To schedule a meeting please contact the conference organizer or send an email to [email protected] .

NOXXON Pharma Enters Second Clinical Collaboration With MSD to Evaluate NOX-A12 in Combination With KEYTRUDA® (Pembrolizumab) in Upcoming Phase 2 Pancreatic Cancer Study

Retrieved on: 
Wednesday, July 21, 2021
Oncology, Health, Clinical trials, Research, Pharmaceutical, Science, Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Pembrolizumab, Checkpoint inhibitor, Noxxon Pharma, Pancreatic cancer, Cancer, NOX-A12, KEYTRUDA, NOXXON, NOX-A12, KEYTRUDA, NOXXON

This Phase 2 study will evaluate the safety and efficacy of NOX-A12, NOXXONs anti-CXCL12 agent, in combination with KEYTRUDA and two different chemotherapy regimens in patients with microsatellite stable pancreatic cancer.

Key Points: 
  • This Phase 2 study will evaluate the safety and efficacy of NOX-A12, NOXXONs anti-CXCL12 agent, in combination with KEYTRUDA and two different chemotherapy regimens in patients with microsatellite stable pancreatic cancer.
  • The vast majority of pancreatic cancer patients have microsatellite stable tumors which are resistant to checkpoint inhibitor monotherapy.
  • MSD will provide pembrolizumab and expert advice for the study protocol, while NOXXON will sponsor the trial that will be conducted in clinical centers in the US and Europe.
  • NOX-A12 is currently developed in second-line pancreatic cancer in combination with Keytruda and in glioblastoma in combination with radiotherapy.